Drug Profile

PRT 7732

Alternative Names: PRT-7732

Latest Information Update: 26 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prelude Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action SMARCA2 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Suspended Solid tumours

Most Recent Events

28 Jan 2026 Prelude Therapeutics terminates its phase I trial for Solid tumours (Late-stage disease, Recurrent, Metastatic disease) in Spain, South Korea, USA, Japan, Germany, Australia due to sponsor decision (PO) (NCT06560645)
04 Nov 2025 Suspended - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Recurrent) in Australia, USA, South Korea, South Korea, South Korea, Germany, Japan, Spain (PO)
28 Apr 2025 PRT 7732 has patent protection worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com